EphA1, Fc Chimera, Recombinant, Human (Ephrin-A1, EPH-related Receptor Tyrosine Kinase Ligand 1, LERK-1, Immediate Early Response Protein B61, Tumor Necrosis Factor alpha-induced Protein 4, TNF alpha-induced Protein 4, EFNA1, EPLG1, LERK1, TNFAIP4)

Katalog-Nummer E3355-01D-50ug

Size : 50ug

Marke : US Biological



E3355-01D EphA1, Fc Chimera, Recombinant, Human (Ephrin-A1, EPH-related Receptor Tyrosine Kinase Ligand 1, LERK-1, Immediate Early Response Protein B61, Tumor Necrosis Factor alpha-induced Protein 4, TNF alpha-induced Protein 4, EFNA1, EPLG1, LERK1, TNFAIP4)

Swiss Prot
P20827
Grade
Highly Purified
Shipping Temp
Blue Ice
Storage Temp
-20°C

Ephrin-A1, also known as B61 and LERK-1, is a member of the Ephrin-A family of GPI-anchored ligands that bind and induce the tyrosine autophosphorylation of Eph receptors. Ephrin-A ligands are structurally related to the extracellular domains of the transmembrane Ephrin-B ligands. Eph-Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression. Human Ephrin-A1 is synthesized with an 18aa signal peptide, a 164aa mature chain, and a 23aa C-terminal propeptide which is removed prior to GPI linkage of Ephrin-A1 to the membrane. It can also be released as a soluble molecule. The mature 21-25kD human Ephrin-A1 shares 85% aa sequence identity with mouse and rat Ephrin-A1. Alternate splicing generates an additional isoform that lacks 22aa in the juxtamembrane region. This short isoform is also expressed on the cell surface and exhibits weakened binding to EphA2. Ephrin-A1 is widely expressed on endothelial and epithelial cells, particularly in the lung, intestine, liver, and skin. It is expressed on resting CD4+ T cells but is down-regulated following activation. Ligation of Ephrin-A1 on CD4+ T cells inhibits cell proliferation and activation, although soluble Ephrin-A1 can promote T cell chemotaxis. In cancer, Ephrin-A1 is expressed by tumor cells as well as on the tumor-associated vasculature. It inhibits tumor cell proliferation and migration but also supports tumor growth by promoting angiogenesis. Soluble Ephrin-A1 additionally promotes neuronal survival and neurite extension.

Recombinant corresponding to aa1-182 from human Ephrin-A1 Fc Chimera expressed in mouse myeloma cell line, NS0.

Molecular Weight:
~46kD

Biological Activity:
Measured by its binding ability in a functional ELISA. When recombinant human EphA2 is coated at 2ug/ml (100ul/well), the concentration of rhEphrin-A1 Fc Chimera that produces 50% of the optimal binding response is found to be ~0.6-3ng/ml.

Storage and Stability:
Lyophilized and reconstituted products are stable for 6 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Source: Recombinant, NS0 cells|Purity: ≥95% (SDS-PAGE). Endotoxin: ≤0.01EU/ug (LAL). |Concentration: ~0.1mg/ml (after reconstitution)|Form: Supplied as a lyophilized powder in PBS. BSA free. Reconstitute with 500ul PBS.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a lyophilized powder in PBS. BSA free. Reconstitute with 500ul PBS.
Purity
≥95% (SDS-PAGE). Endotoxin: ≤0.01EU/ug (LAL).
References
1. Miao, H. and B. Wang (2009) Int. J. Biochem. Cell Biol. 41:762. 2. Pasquale, E.B. (2010) Nat. Rev. Cancer 10:165. 3.Holzman, L.B. et al. (1990) Mol. Cell. Biol. 10:5830. 4. Shao, H. et al. (1995) J. Biol. Chem. 270:5636. 5. Easty, D.J. et al. (1995) Cancer Res. 55:2528. 6. Cui, X.­D. et al. (2010) Int. J. Cancer 126:940. 7. Finne, E.F. et al. (2004) Biochem. J. 379:39. 8. Takahashi, H. and T. Ikeda (1995) Oncogene 11:879. 9. Wohlfahrt, J.G. et al. (2004) J. Immunol. 172:843. 10. Aasheim, H.­C. et al. (2005) Blood 105:2869. 11. Ogawa, K. et al. (2000) Oncogene 19:6043. 12. Liu, D.­P. et al. (2007) Int. J. Oncol. 30:865. 13. Brantley­Sieders, D.M. et al. (2006) Cancer Res. 66:10315. 14. Pandey, A. et al. (1995) Science 268:567. 15. Magal, E. et al. (1996) J. Neurosci. Res. 43:735.